1,771 AbbVie Inc. $ABBV Shares Acquired by Washburn Capital Management Inc.

Washburn Capital Management Inc. grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 36.6% in the third quarter, Holdings Channel.com reports. The firm owned 6,610 shares of the company’s stock after buying an additional 1,771 shares during the period. AbbVie comprises about 0.8% of Washburn Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest position. Washburn Capital Management Inc.’s holdings in AbbVie were worth $1,729,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of ABBV. Gimbal Financial lifted its position in shares of AbbVie by 1,139.4% during the third quarter. Gimbal Financial now owns 37,602 shares of the company’s stock worth $9,836,000 after acquiring an additional 34,568 shares in the last quarter. Talbot Financial LLC grew its position in shares of AbbVie by 0.5% in the third quarter. Talbot Financial LLC now owns 132,343 shares of the company’s stock valued at $34,620,000 after purchasing an additional 647 shares in the last quarter. Prairie Advisory LLC grew its position in shares of AbbVie by 100.2% in the third quarter. Prairie Advisory LLC now owns 2,036 shares of the company’s stock valued at $533,000 after purchasing an additional 1,019 shares in the last quarter. OceanIQ Capital LLC raised its stake in shares of AbbVie by 0.7% during the 3rd quarter. OceanIQ Capital LLC now owns 8,646 shares of the company’s stock valued at $2,372,000 after purchasing an additional 58 shares during the period. Finally, Kaufman Rossin Wealth LLC raised its stake in shares of AbbVie by 69.7% during the 3rd quarter. Kaufman Rossin Wealth LLC now owns 1,785 shares of the company’s stock valued at $467,000 after purchasing an additional 733 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ABBV. Rothschild & Co Redburn raised their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. BMO Capital Markets increased their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Citigroup increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Canaccord Genuity Group raised their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Stock Performance

AbbVie stock opened at $282.95 on Tuesday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40. The stock has a market cap of $499.91 billion, a P/E ratio of 79.93, a PEG ratio of 1.30 and a beta of 0.24. The firm’s fifty day moving average price is $263.44 and its 200-day moving average price is $239.87.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts predict that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s payout ratio is 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s investigational ABBV-466, which targets both IL-23 p19 and integrin α4β7, produced higher endoscopic remission rates in moderate-to-severe Crohn’s disease than either monotherapy at Week 12. The treatment advantage widened by Week 24, while biomarker analyses indicated intestinal tissue repair and barrier restoration. The results improve the drug’s potential as a differentiated next-generation immunology product. AbbVie ABBV-466 Crohn’s disease data
• Positive Sentiment: Analysts viewed the Crohn’s findings favorably because ABBV-466 outperformed AbbVie’s established blockbuster Skyrizi in a mid-stage comparison, highlighting the company’s strategy of combining complementary immune mechanisms. The data could help extend AbbVie’s leadership in inflammatory diseases if confirmed in later-stage trials. AbbVie Crohn’s combination beats Skyrizi
• Positive Sentiment: AbbVie announced its largest-ever presence at the 2026 ESMO Congress, with data from seven oncology assets spanning lung, colorectal, ovarian, prostate and gastric cancers. Updates on antibody-drug conjugates, precision medicines, Elahere and other programs could provide additional pipeline catalysts when presented October 23–27. AbbVie 2026 ESMO oncology data
• Neutral Sentiment: Investors are also watching AbbVie’s neuroscience franchise ahead of quarterly results. Analysts anticipate roughly 16% third-quarter revenue growth from established therapies and newer Parkinson’s treatments, but the outlook will depend on the company’s upcoming earnings report. AbbVie neuroscience franchise outlook

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.